CHMP5 and rheumatoid arthritis: 10/15 (66.7%) of RTX treated patients compared to 15/15 (100%) of HC, 10/11 (90.9%) of patients in the RA control and 0/11 (0%) of patients from the KTR group mounted anti-spike-IgG SARS-CoV-2 antibodies 3 weeks upon 2nd vaccination.